Retatrutide
Also known as LY3437943
Retatrutide is an experimental weekly injection that hits three hormones at once (GLP-1, GIP, and glucagon), showing very large weight-loss results in trials. Not yet approved.
One-dose burn-down
Half-life
6.0 days
Range
5.0 days–7.0 days
Tmax
24 h
Bioavailability
70%
Steady state
~30d
Typical dose
1 mg
Investigational triple agonist (GLP-1 / GIP / glucagon receptor). Once-weekly. Not FDA-approved — in clinical trials.
Mechanism of action
Adds glucagon receptor agonism (raising energy expenditure) to GLP-1/GIP incretin effects, producing large weight-loss in phase 2 trials.
Investigational only. PK values are from early-phase publications and may change. Not available as an approved medicine.
Track Retatrutide for free
Log your doses and PeptideBuddy models Retatrutide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking free